Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL — CLL2-BZAG

Chronic Lymphoid Leukemia Clinical Trial

Official title:
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG Protocol)

Status Active, not recruiting

Clinical Trial Summary

CLL2-BZAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and venetoclax (ABT-199) in patients with relapsed/refractory CLL.

Clinical Trial Description

In the CLL2-BZAG trial will be included a total of 40 patients with relapsed or refractory CLL in need of treatment. This trial will evaluate a debulking with two cycles bendamustine (only for patients with a high tumor load), followed by an induction and maintenance treatment with obinutuzumab, zanubrutinib and venetoclax in patients with relapsed/refractory CLL. Thus, this trial combines one established (chemotherapy) and three novel, synergistic (antibody, Bruton's tyrosine kinase(BTK)-inhibitor and Bcl-2 antagonist) principles of action in order to achieve deep and long lasting remissions with a short duration of treatment. Additionally, this trial has an extensive accompanying scientific program aiming at a better understanding of the kinetics of response and clonal evolution of CLL. ;

Study Design

Related Conditions & MeSH terms

Chronic Lymphoid Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid

Clinical Trial Details

NCT number	NCT04515238
Study type	Interventional
Source	German CLL Study Group
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	October 1, 2020
Completion date	March 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00406809` - A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies	Phase 1/Phase 2
Recruiting	`NCT03766763` - Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A	Phase 2
Active, not recruiting	`NCT04608318` - Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)	Phase 3
Active, not recruiting	`NCT04883749` - Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL	Phase 2
Recruiting	`NCT03804372` - The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide	Phase 2
Active, not recruiting	`NCT00788684` - Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers	Phase 1
Terminated	`NCT01518959` - The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases	Phase 3
Completed	`NCT03787264` - Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL	Phase 2
Recruiting	`NCT03852407` - Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning	Phase 2
Recruiting	`NCT05350826` - Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia	N/A